Aquestive Therapeutics Hit by Class Action Over FDA Anaphylm Disclosure Failures

The Portnoy Law Firm has filed a class action lawsuit against Aquestive Therapeutics, Inc., alleging securities fraud and material misrepresentations regarding FDA approval prospects for its Anaphylm drug. The lawsuit targets investors who purchased AQST securities during an eight-month window from June 16, 2025 through January 8, 2026, claiming the company made false statements about regulatory progress while concealing critical deficiencies identified by the FDA in its New Drug Application. The legal action follows a devastating 37% stock price decline announced on January 9, 2026, when Aquestive disclosed that the FDA had identified deficiencies in the Anaphylm NDA filing.

The Alleged Misconduct and Timeline

According to the lawsuit filed by the Portnoy Law Firm, Aquestive Therapeutics made materially false and misleading statements regarding the regulatory pathway and approval prospects for Anaphylm, a drug candidate that represented significant commercial opportunity for the biopharmaceutical company. The core allegation centers on the company's failure to disclose that the FDA had already identified deficiencies in the New Drug Application (NDA) submission—information that would have been material to investors evaluating the likelihood and timing of regulatory approval.

Key timeline details of the alleged misconduct:

• June 16, 2025: Class period begins; investors begin purchasing Aquestive securities
• January 8, 2026: Class period ends; last date of allegedly fraudulent statements
• January 9, 2026: Aquestive publicly discloses FDA-identified deficiencies in Anaphylm NDA
• Stock reaction: Share price falls more than 37% following the disclosure
• May 4, 2026: Deadline for filing lead plaintiff motion in the class action

The approximately eight-month gap between when the FDA likely communicated deficiencies to Aquestive and when the company publicly disclosed this information forms the basis of the alleged securities fraud. Investors who purchased shares during this period allegedly did so without knowledge of material information that directly impacted the regulatory prospects of the company's most prominent clinical-stage asset.

Market Context and Competitive Landscape

Aquestive Therapeutics operates in the specialty pharmaceutical sector, where regulatory approval status serves as a primary driver of stock valuation and investor sentiment. Biopharmaceutical companies typically trade on forward-looking expectations regarding pipeline success and regulatory timelines. For AQST, Anaphylm appeared to represent a key value driver, making accurate disclosure of regulatory progress essential to fair pricing.

The biopharmaceutical sector has witnessed increased regulatory scrutiny and investor sensitivity regarding disclosure practices. The FDA's identification of deficiencies—rather than outright rejection—typically signals that additional data, manufacturing information, or clarifications are required before approval. However, deficiencies can substantially delay approval timelines and increase development costs, making their disclosure material to investment decisions.

Class action litigation around biotech regulatory disclosures has become increasingly common as:

• Investors demand greater transparency regarding FDA communications
• Courts recognize that concealed regulatory setbacks constitute material information
• Enforcement focus on corporate disclosure practices has intensified
• Shareholder litigation has become a mechanism for accountability in the sector

The 37% stock decline following the January 9 disclosure suggests the market had substantially mispriced Aquestive's securities based on the incomplete information available during the class period, supporting the legal argument that the undisclosed deficiencies were indeed material.

Investor Implications and Litigation Significance

For AQST shareholders, this class action represents potential recovery mechanisms for losses sustained during the fraudulent trading period. The lawsuit structure allows investors who purchased shares between June 16, 2025 and January 8, 2026 to participate in any eventual settlement or judgment without individually pursuing claims.

The May 4, 2026 deadline for lead plaintiff motions is significant because lead plaintiffs receive named status and typically greater involvement in settlement negotiations. Institutional investors and individuals with substantial losses during the class period are likely to compete for this designation.

Broader implications for the sector include:

For Regulatory Disclosure Standards: The case underscores that biotech companies must promptly and transparently communicate FDA feedback, even when communications indicate remediable deficiencies rather than outright rejection.

For Investor Confidence: Successful class actions establish legal precedent that incentivizes more rigorous disclosure practices, potentially benefiting long-term market integrity in the biotech sector.

For Stock Valuations: The rapid repricing following the deficiency disclosure demonstrates how regulatory information asymmetries can create significant valuation risk, encouraging market participants to scrutinize biotech company disclosures more carefully.

For Corporate Liability: Pharmaceutical and biotech companies face escalating litigation risk when FDA communications are withheld or delayed in public disclosure, potentially influencing internal corporate governance and investor relations practices.

Investors in AQST and similar clinical-stage biopharmaceutical companies should evaluate disclosure practices and regulatory communication transparency as risk factors in investment analysis. This case illustrates how a single material omission can trigger substantial shareholder value destruction and subsequent litigation exposure.

The litigation against Aquestive Therapeutics serves as a reminder that in capital markets, the timeliness and completeness of material disclosures—particularly regarding regulatory milestones that directly impact valuation—are not mere compliance formalities but fundamental requirements for fair and efficient price discovery. As the case progresses toward the May 4 deadline and beyond, market participants will be monitoring outcomes that could influence disclosure practices and litigation risk across the broader biopharmaceutical sector.